Introducing Scott Kozak: InSingulo's First US Business Development Team Member
July 2023 - We are thrilled to announce the arrival of Scott Kozak, the newest member of our growing family at InSingulo. With a background in marketing and international business, Scott brings a wealth of experience and expertise to our team. His passion for the pharmaceutical and life sciences industry, coupled with his entrepreneurial spirit, makes him an invaluable asset as we embark on our journey to revolutionize drug discovery. In this blog post, we had the opportunity to sit down with Scott and learn more about his background, his excitement for InSingulo's technology, and his interests outside of work.
Scott's Background and Expertise
Scott's journey in the pharmaceutical and life sciences industry began in 1992, and since then, he has worked with major pharmaceutical companies, start-ups, and even founded four of his own start-up ventures. His vast experience spans various roles, giving him a holistic understanding of the industry. Notably, Scott has been an instructor of Entrepreneurship at the Connecticut Center for Entrepreneurship and Innovation (CCEI) at the University of Connecticut Graduate School of Business. Currently, he serves as an Entrepreneur in Residence at CCEI and Yale Ventures, further showcasing his commitment to fostering innovation and growth in the biotech sector.
Excitement for InSingulo
When asked about what excites him the most about InSingulo, Scott expressed enthusiasm for the company's unique technology and instrument. InSingulo's cutting-edge solution offers a glimpse into the drug binding process at the single-cell level, allowing for informed decisions during the drug discovery process. Scott recognizes the immense potential of this technology in optimizing drug development by enabling a deeper understanding of drug-target interactions. He believes that InSingulo's approach will revolutionize the industry and open new possibilities for developing effective therapies.
Targeting Protein Therapies
Scott firmly believes that InSingulo's technology will benefit any company or institution involved in developing target proteins as potential therapies. By providing insights into the drug binding process at the single-cell level, InSingulo's solution empowers researchers to make more informed decisions about which compounds should be taken forward in the development process. This level of precision and efficiency has the potential to accelerate the discovery and development of novel therapies, ultimately benefiting patients and advancing healthcare.
Beyond business
While Scott is passionate about his work in the biotech industry, he also finds joy in his personal life. In his spare time, he cherishes moments spent with his two daughters and family. Excitingly, his family is expanding with the addition of his fiancée and her four daughters. Scott embraces an active lifestyle, engaging in activities such as hiking and playing softball on the weekends. He also enjoys participating in bowling leagues during the Fall and Winter seasons.
Scott Kozak's addition to the InSingulo team marks an exciting milestone in our journey to revolutionize drug discovery. With his extensive experience, passion for innovation, and belief in InSingulo's unique technology, Scott is well-equipped to spearhead business development efforts in the United States. We look forward to the expertise and insights he will bring to the table as we forge ahead in optimizing the drug discovery process. Beyond his professional accomplishments, Scott's commitment to family and his active lifestyle exemplify the values we hold dear at InSingulo. We extend a warm welcome to Scott and eagerly anticipate the future successes we will achieve together.